The phosphotyrosine (pTyr) adapter Shc/ShcA is a major connector in various tyrosine kinase signalings following a variety of stimulation such as growth factor/ neurotrophin, as well as in those following calcium in¯ux and integrin activation. As in other tissues, Shc has been implicated in neuronal signalings; however, recent evidence suggests that N-Shc/ShcC and Sck/ShcB would take over most of the roles of Shc in mature central neurons, and switching phenomena between Shc and NShc expression were observed in several neuronal paradigms. Little is, however, known as to the signaloutput dierences between Shc and N-Shc. Here we determined the ecacy of Shc and N-Shc toward Erk activation in NGF-treated PC12 cells, and found that NShc transduced Grb2/Sos/Ras-dependent Erk activation less eciently than Shc. This was mainly because N-Shc has only one high-anity Grb2-binding site, whereas Shc has two such sites. Phosphopeptide mapping revealed that N-Shc has novel tyrosine-phosphorylation sites at Y259/Y260 and Y286; in vivo-phosphorylation of these tyrosines was demonstrated by site-speci®c anti-pTyr antibodies. Phosphorylated Y286 bound to several proteins, of which one was Crk. The pY221/pY222 site, corresponding to one of the Grb2-binding sites of Shc, also preferentially bound to Crk. The phosphorylationdependent interaction between N-Shc and Crk was demonstrated in vitro and in vivo. These results indicate that N-Shc has speci®c features of signal-output, and further suggest that the switching between Shc and NShc during neural development and regeneration would lead to dierentiation of downstream signalings.
Introduction
Shc gene products serve as adapter proteins in tyrosine kinase signaling following a range of extracellular stimulations (Bon®ni et al., 1996) . The Shc proteins have two phosphotyrosine (pTyr)-recognition modules, an amino-terminal pTyr-binding (PTB) domain and a carboxyl-terminal SH2 domain, which bind to various pTyr-containing peptides with dierent speci®cities (van der Geer et al., 1996a) . Shc thereby associates with a wide variety of activated receptors, and consequently becomes phosphorylated at its tyrosine residues 239, 240 and 317 (Gotoh et al., 1996; van der Geer et al., 1996b; Harmer and DeFranco, 1997) . Both pY239 and pY317 form an optimal binding site for the SH2 domain of another adapter protein, Grb2 (van der Geer et al., 1996b; Thomas and Bradshaw, 1997) . Grb2 also binds through its SH3 domain to the Ras guanine nucleotide exchange factor Sos1/2. The phosphorylated Shc thus recruits the Grb2 ± Sos complex to the plasma membrane, leading to the activation of membranebound Ras (Rozakis-Adcock et al., 1992) . Additional Shc partners have been described, including Src family kinases and adaptins (Okabayashi et al., 1996; Wary et al., 1998) . Shc was also implicated in JNK activation in B cells (Hashimoto et al., 1999) , and further the p66 isoform of Shc was demonstrated to regulate oxidative stress-induced apoptosis and organismic lifespan (Migliaccio et al., 1999) . Collectively, Shc appears to be a scaold for the assembly of a variety of pTyrdependent signaling complexes and has been implicated in divergent cellular signalings including Ras ± Erk activation and other pathways.
Studies on PC12 cells have elucidated that Shc plays a pivotal role in Ras ± Erk activation following nerve growth factor (NGF) stimulation and Ras-dependent neurite extension (Rozakis-Adcock et al., 1992; Obermeier et al., 1994; Stephens et al., 1994) . When a mutant of the Shc binding site in the TrkB receptor, which binds to brain-derived neurotrophic factor and neurotrophin-4, was introduced into mice by homologous recombination, Erk activation in response to both neurotrophins was signi®cantly reduced (Minichiello et al., 1998) . These data indicated that Shc plays a fundamental role in regulating and/or modifying neuronal signalings as in other tissues (Lai and Pawson, 2000) . However, the mRNA level of Shc, which is widely expressed in most tissues, was found to be remarkably low in the adult brain (Nakamura et al., 1996; Conti et al., 1997) . We and others recently isolated two closely related Shc homologs, N-Shc/ShcC and Sck/ShcB, and found that they are expressed in neural tissues; in particular, high-level expression of NShc was speci®c to the adult brain and spinal cord (Nakamura et al., 1996; O'Bryan et al., 1996b; Pelicci et al., 1996) . We further proposed that these two Shcrelated molecules exert neuronal adapter function instead of Shc, particularly in the adult central nervous system Kojima et al., 2001) . Recent report of null mutants of N-Shc and Sck indicates that N-Shc and Sck have physiological functions in survival of postmitotic sensory and sympathetic neurons (Sakai et al., 2000) , whereas biochemical features of N-Shc (or Sck)-mediated signalings still remain largely unknown.
Shc and N-Shc show dynamic temporal and spatial exchange of gene expression in several paradigms of the nervous system. First, in nerve-injured motoneurons, Shc mRNA expression was transiently upregulated markedly, whereas N-Shc was down-regulated (Tanabe et al., 1998) . Second, in the central nervous system, the level of Shc protein was strictly regulated during embryonic development, and its level was sharply decreased when embryonic neurons made the transition into a postmitotic state (Conti et al., 1997) . N-Shc, whose level of expression in immature neurons was trace, was dramatically induced around birth and highly expressed in the adult brain (Nakamura et al., 1996; Sakai et al., 2000) . In contrast, Sck and Grb2 transcripts remained expressed at constant levels throughout these processes (Conti et al., 1997; Tanabe et al., 1998) . The switching phenomena of expression between Shc and N-Shc may be accompanied by certain exchange of functions performed by these two related signaling molecules. Structural conservation among three members of the Shc family is impressive; however, their amino acid sequences diverged extensively in their internal CH1 domain, even though several sites, i.e., two potential Grb2 binding sites and a potential adaptin binding site, are conserved there . To explore dierential signal-outputs, we have dissected out critical signal-output residues of Shc and N-Shc in the CH1 domain. As reported herein we found quantitative and qualitative dierences in signaling properties between these two adapter molecules.
Results

N-Shc transduces Erk activation signal less efficiently than Shc
To obtain a clue for the biological meanings of the phenotypic exchange of Shc vs N-Shc gene expression during development and regeneration, we ®rst compared the level of Grb2/Sos/Ras-dependent Erk activation mediated by Shc and N-Shc. This is the best-characterized function of Shc family as adapter molecules (Rozakis-Adcock et al., 1992; Bon®ni et al., 1996) . To compare the contribution of Shc and N-Shc to this pathway, we chose NGF-induced Erk activation in PC12 cells for the following reasons: (i) Both Shc and N-Shc bind to the TrkA receptor with relatively equal anities, whereas this receptor does not interact directly with Grb2 Obermeier et al., 1994; O'Bryan et al., 1996a; Nakamura et al., 1998) ; thus the direct route from TrkA to Grb2 is negligible. (ii) Shc and Sck, but not N-Shc, are expressed in PC12 cells, and the TrkA-binding of Sck is inecient . Therefore, in PC12 cells, Shc should be the only ecient mediator among Shc family members in NGF-induced Erk activation, and thus we can determine the eect of the exogenously added Shc or N-Shc over the basal eect of endogenous Shc. NGF-induced activation of Erk can be monitored by measuring the rate of transcription via Elk-1, one of the targets of activated Erk (Whitmarsh et al., 1995) . We performed a transient reporter assay using the Gal4 ± Elk1 fusion transcription factor (Hauser et al., 1995) . Overexpression of Shc in PC12 enhanced the NGF-dependent activation of Elk-1 by 1.3 ± 1.4-fold, whereas N-Shc blocked 30 ± 40% of the activation of NGF (Figure 1a) . The speci®c reduction of NGF-induced Elk-1 activation by N-Shc suggests either that N-Shc potentially inhibits Erk activation or that N-Shc is a less ecient mediator of Erk activation than Shc and the competitive binding of N-Shc to the Shc binding site on TrkA leads to the reduced Erk activity. To assess these two possibilities, we compared the level of Elk-1 activation following the transfection with wild-type (WT) or the 3F mutant of N-Shc; the N-Shc 3F (Y221/222/304F) mutant, in which potential Grb2-binding sites were mutated to Phe, would be expected to lose Grb2-binding ability just like the corresponding Shc 3F (Y239/240/317F) mutant (Thomas and Bradshaw, 1997) . The Elk-1-dependent transcription in N-Shc 3F mutant-transfected cells was signi®cantly lower than that in WT NShc-transfected cells (Figure 1b ). This indicates that NShc is capable of mediating the Erk activation signal, although the level of activation by N-Shc is lower than that by Shc.
The quantitative dierence in Erk activation between Shc and N-Shc can be directly examined by measuring the level of activation of transfected Erk2. We transfected PC12 cells with an expression vector encoding myc-tagged Erk2 along with the WT or 3F mutant of T7 peptide-tagged Shc or N-Shc cDNA. Following NGF stimulation, myc-tagged Erk2 was immunoprecipitated and analysed for activation by use of a phospho-Erk speci®c antibody (Figure 1c To elucidate primary signal-output sites for Erk activation, we performed mutational analysis of potential Grb2-binding sites. In the Shc CH1 domain, phosphorylation of Y239/Y240 and Y317 results in the generation of two Grb2 docking sites, which leads to Erk activation through the Ras pathway (van der Geer et al., 1996b; Harmer and DeFranco, 1997; Thomas and Bradshaw, 1997) . Corresponding residues in N-Shc are Y221/Y222 and Y304 (Figure 2a) . Thus, we examined whether each of these two sites of N-Shc could bind to Grb2 when phosphorylated. We stimulated PC12 cells expressing either WT N-Shc, Y221/222F, Y304F or 3F mutant with NGF. The cell lysates were immunoprecipitated with anti-T7 antibody, and the immunoprecipitates were immunoblotted with anti-Grb2, anti-pTyr (RC20) and anti-T7 antibodies. Upon NGF stimulation, WT and Y221/222F N-Shc bound to Grb2 at similar levels, whereas the interaction of Y304F N-Shc with Grb2 was very much reduced (Figure 2b, top) . This indicates that phosphorylated Y304, but not Y221/Y222, was a major Grb2 docking site of N-Shc. As for the phosphorylation status of WT and mutant N-Shc proteins in response to NGF, both Y221/222F and Y304F mutants were phosphorylated at a somewhat lower level than WT N-Shc, and the 3F mutant displayed only residual phosphorylation (Figure 2b , middle). The WT and mutant N-Shc proteins recovered from the transfected cells were equal in amount (Figure 2b , bottom). We therefore conclude that pY304 of N-Shc is a major Grb2 docking site, and further assume that We further con®rmed that phosphorylated Y304 was a major Grb2 binding site in N-Shc by use of phosphopeptide anity puri®cation. We made a dually phosphorylated peptide based on the sequence around Y221 and Y222 (residues 218 ± 229) and another phosphopeptide including Y304 (residues 299 ± 310). The pY304-containing phosphopeptide bound to Grb2, whereas the pY221/pY222 peptide bound to Grb2 with far less anity ( Figure 3a ). Peptide phosphorylated on either Y221 or Y222 failed to associate with Grb2 at a detectable level (data not shown). Since, in Shc, phosphorylation of Y239/Y240 is known to induce ecient binding to Grb2 (van der Geer et al., 1996b; Harmer and DeFranco, 1997) , we then compared the Grb2 binding capacity of the corresponding twin tyrosines among the Shc family members. Both pY239/pY240 of Shc and pY316/pY317 of Sck bound to Grb2 eciently; however the Grb2 binding of pY221/pY222 of N-Shc was signi®cantly weaker (Figure 3b) . Thus, N-Shc transduces Erk activation signal less eciently than Shc, primarily because NShc has only one high-anity Grb2 docking site, i.e., Y304.
Identification of novel tyrosine phosphorylation sites, Y259/260 and Y286, on N-Shc
These results may, in turn, suggest that N-Shc has additional binding partners besides Grb2. The N-Shc 3F (Y221/222/304F) mutant showed residual phosphorylation following NGF stimulation (Figure 2b , middle), suggesting that additional tyrosine phosphorylation sites may be present in N-Shc. We performed phosphopeptide mapping analysis using GST-fused NShc protein, and found that N-Shc phosphorylated by TrkA in vitro was resolved into at least seven phosphopeptides (Y1 through Y7, Figure 4a ). Given that N-Shc is phosphorylated at Y221/Y222 and Y304, (YY, lanes 1, 3, 5) and peptides phosphorylated at both tyrosine residues (pYpY, lanes 2, 4, 6) based on the sequences around Y221/Y222 (N-Shc), Y239/Y240 (Shc) and Y316/Y317 (Sck) were immobilized and analysed as described above Oncogene Distinct signaling properties of Shc and N-Shc T Nakamura et al three phosphopeptide (singly-and dually-phosphorylated Y221/Y222 peptides and pY304 peptide) should appear. Therefore, this result suggests that N-Shc should have additional phosphorylation sites. We also obtained tryptic phosphopeptide maps of N-Shc protein phosphorylated in vitro by other tyrosine kinases, TrkB, v-Src and EGFR. The overall patterns of the phosphopeptide maps generated by these tyrosine kinases were similar, although there were some dierences among these maps (Figure 4a ± d) .
To characterize each spot in the phosphopeptide maps, we performed phosphopeptide mapping using various Y/F mutants phosphorylated by EGFR (Figure 4g ± j) . As shown in Figure 4d , WT N-Shc phosphorylated by EGFR in vitro was resolved into seven phosphopeptides (Y1 through Y7), similar to those by TrkA (Figure 4a ). Y4 and Y7 were absent from the map of the Y221/222F N-Shc (compare Figure 4d and g). The analysis using a single mutant, i.e., Y221F or Y222F, revealed that Y4 and Y7 represented a dually and a singly phosphorylated form, respectively (data not shown). Y5 was absent from the map of the Y304F N-Shc (Figure 4h ).
We were surprised to ®nd that neither phosphopeptides including Y221/Y222 (Y4 and Y7) nor Y304 (Y5) corresponded to the major spots in Figure 4a ± d. Thus, we searched for additional potential phosphoacceptor sites of N-Shc. The PTB domain of N-Shc has ®ve tyrosines. GST-fused N-Shc PTB domain was phosphorylated by EGFR in vitro and similarly analysed. However, the level of N-Shc PTB domain phosphorylation was signi®cantly lower than that of the fulllength one, and the spots in phosphopeptide map of the N-Shc PTB domain did not correspond to any major spots in the map of the full-length N-Shc (data not shown). Therefore, it is unlikely that the major spots in Figure 4a ± d were derived from the PTB domain. The CH1 domain of N-Shc has additional tyrosines (Y259/Y260 and Y286) besides Y221/Y222 and Y304 (Figure 2a ). Then, we tested them by making a series of Y/F mutants. In the map of the Y259/260F N-Shc, Y2 and Y6 were undetectable (see Figure 4d and I). In the map of a single mutant, i.e., Y259F or Y260F, Y2 was absent and Y6 partly disappeared (data not shown). Therefore, we inferred that Y2 should represent a dually-phosphorylated form and Y6 a single phosphorylation. Importantly, this identi®ca-tion was supported by the prediction of phosphopeptide mobility based on amino acid composition following the standard procedure (Boyle et al., 1991) . Further, in the map of Y286F N-Shc, Y1 and Y2 were absent (Figure 4j) . Y2, however, corresponded to the dually phosphorylated peptide containing Y259/Y260. Therefore, Y1 should be the phosphopeptide containing Y286, and this was also consistent with the predicted phosphopeptide mobility. A likely explanation of the reason why Y1 and Y2 disappeared in the Y286F map was that unexpected conformational change induced by the mutation at Y286 lead to the change of accessibility of the tyrosine kinase to a particular tyrosine (Y259 or Y260) close to Y286, although we could not exclude other possibilities. As shown in Figure 4f , we conclude that N-Shc has novel phosphoacceptor tyrosines, i.e., Y259/Y260 and Y286, at least in vitro, although the identity of Y3 still remains unknown.
To test whether these N-Shc sites are also phosphorylated in vivo, we prepared 32 P-labeled NShc from EGF-stimulated COS-1 cells, and analysed it by phosphopeptide mapping (Figure 4e ). Y286 (spot Y1), which was highly phosphorylated by all tyrosine (Figure 4a ± d) , was one of the most highly-phosphorylated residues following EGF stimulation (Figure 4e ). Also, a singly-phosphorylated form of Y259/Y260 (spot Y6) was reproducibly observed. Therefore, these novel tyrosine phosphorylation sites of N-Shc were eciently phosphorylated in vivo as well as in vitro. The in vivo phosphorylation of Y221/Y222 (spots Y4 and Y7) occurred at a relatively high level, and Y304 (spot Y5) at a detectable level. The unidenti®ed spot (Y3) was barely phosphorylated in vivo. We also noted additional phosphopeptides in the map of the in vivo-phosphorylated N-Shc, as circled in Figure 4e . We have yet to identify these spots; however, we suppose that these peptides may correspond to Ser/Thr-phosphorylation by certain Ser/Thr kinase(s) activated following EGFR activation and/or constitutively activated Ser/Thr kinase(s) even in serum-starved cells. Both possibilities were supported by results of mobility-shift experiments using Ser/Thrspeci®c phosphatase PP2A (Nakamura et al., unpublished) .
To demonstrate the in vivo phosphorylation of Y259/ 260 and Y286 directly, we generated site-speci®c antipTyr antibodies against pY259 and pY286. The immunoblotting with the anti-pY259 antibodies of WT or Y259/260F mutant of N-Shc recovered from EGF-treated cells (left panel of Figure 5 ) demonstrated the speci®city of the anti-pY259 antibodies (lanes 2 and 3 in the anti-pY259 blot). The speci®city of the antipY286 antibodies was similarly con®rmed (lanes 2 and 4 in the anti-pY286 blot). Both of these site-speci®c anti-pTyr antibodies clearly recognized WT N-Shc in EGF-treated but not in untreated cells (lanes 1 and 2) . Thus EGF-dependent phosphorylation of Y259 and Y286 was directly demonstrated in vivo. These two tyrosines (Y259 and Y286) were also phosphorylated following NGF stimulation in the transfected PC12 cells (right panel of Figure 5 ). Although in vivophosphorylation of these two sites upon EGF treatment was easily detected by use of site-speci®c antipTyr antibodies and by phosphopeptide mapping (Figure 4e ), a very little decrease was observed in the reactivity for the Y259/260F and Y286F mutants with the pan-pTyr antibody (anti-pTyr blot in Figure 5 ) and a large decrease was observed for the 3F (Y221/222/ 304F) mutant with the same antibody ( Figure 2b , middle); this is possibly because this kind of antibody recognizes a variety of pTyr-containing sequences more or less unevenly.
Novel binding partners of phosphorylated tyrosines on N-Shc
What would then be a likely function(s) of the newly identi®ed phosphorylation sites, Y259/260 and Y286? They could serve as binding sites for modules such as SH2 or PTB domains that recognize pTyr. To test whether these phosphorylation sites could interact with novel partners, we performed phosphopeptide-anity puri®cation using various pTyr-containing peptides. Peptide phosphorylated at either Y259 or Y260, at both Y259 and Y260, at Y286 and their controls (unphosphorylated peptides) were immobilized on NHS-Sepharose and incubated with lysates from SH-SY5Y neuroblastoma cells. Bound proteins were resolved by SDS ± PAGE and visualized by silverstaining. Peptide phosphorylated at Y286 (pY286) bound to a number of proteins with molecular weights of 170, 120, 70, 48 and 40 kDa (Figure 6a , lanes 1 and 2). For comparison, bound proteins to pY304 were presented (Figure 6a, lanes 3 and 4) ; the existence of Grb2 and Grb2-associating Sos and dynamin (Miki et al., 1994) among the pY304-bound proteins was con®rmed by immunoblotting (data not shown).
Among the aforementioned pY286-binding proteins, the one at 40 kDa (p40) (Figure 6a , lane 2) could be CrkII. CrkII is an SH2-containing adapter molecule of 40 ± 42 kDa and has been shown to work in parallel with Grb2 (Matsuda and Kurata, 1996) . The sequence around Y286 of N-Shc (YSTP) satis®es the minimal requirement for the binding site for the Crk SH2 domain, i.e., YXXP (Matsuda and Kurata, 1996) . In addition, one of the proteins that bound to the pY221/ pY222 anity beads had a similar mobility as p40 (data not shown), and a sequence similar to the consensus for Crk SH2 binding (YNHP) was also found around Y222 (YNSIP). Thus, eluates from each of the pY221/pY222, pY286 and pY304 anity beads were analysed by immunoblotting with anti-Crk antibody. We found that both pY221/pY222 and pY286 bound to CrkII, and to its splicing variant CrkI (Figure 6b, top) . Together with Crk, we further found that C3G, constitutively associating with Crk (Matsuda et al., 1994) , also bound to the pY221/pY222 and pY286 anity beads (Figure 6b, bottom) . The Crk binding of pY221/pY222 of N-Shc is speci®c, because neither corresponding pTyr residues of Shc (pY239/ pY240) nor Sck (pY316/pY317) were capable of binding to Crk (Figure 6c) .
To extend these phosphopeptide-binding studies to full-length N-Shc, GST-fused N-Shc protein was Figure 6d demonstrated that GST-NShc that was phosphorylated by Elk bound to Crk eciently, whereas unphosphorylated GST-N-Shc was unable to bind to Crk. The N-Shc-Crk binding was direct, because Elk (and other phosphoproteins) did not associate with the puri®ed GST-phospho-N-Shc (data not shown). Next, various Y/F mutants of GST-N-Shc were similarly phosphorylated and tested for their Crk-binding (Figure 6e ). WT and the Y304F mutant bound to Crk at similar levels, whereas mutation of either Y221/222 or Y286 resulted in a large decrease in Crk-binding, and the Crk-binding was almost abolished by the Y221/222/286F mutation. This is consistent with the result of phosphopeptide-binding assays (Figure 6b ), indicating that both pY221/pY222 and pY286 constitute Crk binding sites in N-Shc. To test for association of N-Shc with Crk in vivo, anti-T7 immunoprecipitates from control and EGF-stimulated COS-1 cells transfected with T7-tagged N-Shc and CrkI were analysed by anti-Crk immunoblotting (Figure 6f) . The immunoprecipitated N-Shc bound to CrkI only after EGF stimulation. The concurrent tyrosine-phosphorylation of N-Shc following EGF treatment was con®rmed. Collectively, these data demonstrate that pY286 and pY221/pY222 sites of N-Shc could associate with pTyr-binding proteins other than Grb2; these potential partners including Crk may contribute to N-Shc-speci®c function in mature neurons.
Discussion
When neurons respond to various stimuli during development/regeneration or in the case of synaptic plasticity, certain speci®c adapter molecules could become potential modulators of multiple signaling pathways, including those involved in growth factor/ neurotrophin signaling and neurotransmission. Among various adapters and scaold proteins, Shc-family molecules, implicated in Ras-mediated and other signalings, could be a critical signal modulator (Lai and Pawson, 2000) or the`go-between' (Bourne, 1995) . Recent evidence indicates that multiple eectors of Ras, i.e., Raf, PI 3-kinase and RalGDS, are coordinately regulated; and thus quantitative dierences in Ras activity can lead to qualitatively dierent biological responses (Pawson and Saxton, 1999; Shields et al., 2000) . For example, targeted disruption of the mouse shc gene revealed that Shc regulates cell sensitivity of growth factor-induced Ras ± Erk activation (Lai and Pawson, 2000) . Drosophila Shc mediates a speci®c aspect of Ras signaling following the activation of a subset of receptor tyrosine kinases (Luschnig et al., 2000) . Shc is thus thought to amplify and coordinate Ras ± Erk and other pathways depend- ing on various situations. Therefore, both quantitative and qualitative characteristics of signal-outputs have become important issues in signal discrimination by Shc family members. We have provided evidence that the ecacy of mediating Ras ± Erk activation is signi®cantly dierent between Shc and N-Shc. This is mainly based on the fact that Shc has two Grb2-binding sites, whereas NShc has only one such site. Additionally, Erk inhibitory eect of unidenti®ed pathway through N-Shc may partly contribute to this quantitative dierence in Erk activation; this possibility might require a future investigation. Eventually, when relative amounts of Shc and N-Shc are altered, downstream signaling should lead to dierent outcomes. N-Shc is predominantly expressed in mature central neurons including motoneurons; whereas Shc is abundant in developing neurons (Nakamura et al., 1996; Conti et al., 1997; Sakai et al., 2000) , although there is no temporal exchange between Shc and N-Shc gene expression during neuronal dierentiation of PC12 cells (Sato et al., unpublished observations) . Mature motoneurons utilize mostly N-Shc, whereas the injured motoneuron begins to switch from N-Shc to Shc following axotomy (Tanabe et al., 1998) . One possible explanation for this is that the quantitative balance between Shc and N-Shc can modulate the quality of the closely-connected signalings, which would further lead to neuronal dierentiation, maturation, regeneration, etc.
Crk, a novel candidate for the N-Shc partner, contains SH2 and SH3 domains and can induce transformation in ®broblasts and neuronal dierentiation in PC12 cells; further, Crk recruits paxillin, p130
Cas and DOCK180 and becomes a crucial component in the signaling complexes involved in cytoskeletal reorganization (Matsuda and Kurata, 1996) . Crk has also been implicated in the activation of Erk and JNK (Matsuda et al., 1994; Tanaka et al., 1997; York et al., 1998) . Although several groups reported the association of Crk with Shc following growth-factor stimulation, the binding is rather weak, and it remains unclear whether the interaction is primarily direct or not (Matsuda et al., 1994; Torres and Bogenmann, 1996) . A sequence similar to the consensus sequence for the Crk SH2 binding (YNHP) is found in Shc only at Y240 (YNDFP). Phosphopeptide-binding studies demonstrated that pY221/pY222 of N-Shc bound to Crk with much higher anity than pY239/pY240 of Shc; therefore, the association between N-Shc and Crk would be much tighter than the Shc ± Crk association. And further, we detected the phosphorylation-dependent interaction between N-Shc and Crk in vitro and in vivo, although the observed in vivo interaction between N-Shc and Crk seems somewhat unstable, particularly in the case of CrkII (data not shown), as in other Crk partners (Ribon and Saltiel, 1996; Nakashima et al., 1999) .
What would then be the physiological consequences of the N-Shc-Crk interaction? Rap1 activation accomplished by assembly of a complex including Crk and C3G is reported to induce neuronal dierentiation of PC12 cells via B-Raf-mediated Erk activation (York et al., 1998; Kao et al., 2001) . However, in PC12 cells used in this study, NGF-induced Rap1 activation made a very little contribution to Erk activity (data not shown), as observed in other laboratories (Zwartkruis et al., 1998; Busca et al., 2000; Yamashita et al., 2000) . Thus, in our opinion, Rap1 ± GTP level can be aected by the association of Crk with transiently-expressed NShc upon ligand stimulation, whereas this change of Rap1 activity cannot contribute to Erk activation in PC12 cells used here. This view is consistent with our observation that N-Shc transduced Erk activation less eciently than Shc (Figure 1 ). We rather think that NShc/Crk-mediated signaling should lead to other targets, such as cytoskeletal plasticity and actin dynamics, in which Crk was shown to be implicated (Nakashima et al., 1999; Escalante et al., 2000) ; these targets in neuronal cells will be subjects of future research. Furthermore, a variety of other proteins binding to the pY286 peptide (Figure 6a ) may contribute to signaling networks through N-Shc in mature neurons.
Our data also suggest that N-Shc has potential Ser/ Thr phosphorylation sites. In Shc, serine phosphorylation is induced by various extracellular stimulants, e.g., EGF, ®broblast growth factor-2 and 12-O-tetradecanoylphorbol-13-acetate (TPA) (van der Geer et al., 1996b; El-Shemerly et al., 1997; Migliaccio et al., 1999) , and has been suggested to contribute to Ras ± Erk activation (El-Shemerly et al., 1997) . Recently, however, p66
Shc -speci®c phosphorylation of Ser36 has been shown to mediate oxidative stress response, which is distinct from the Ras ± Erk route (Migliaccio et al., 1999) . If N-Shc has such speci®c Ser/Thr phosphorylation sites, they could be utilized to further dierentiate downstream signals, or also be used for signaling crosstalk.
In conclusion, our ®ndings of apparently dierent ecacy of Shc and N-Shc in Erk activation, unique and novel pTyr signal-output from N-Shc, and potential candidates for N-Shc partners including Crk shed light on the biological signi®cance of the spatiotemporal exchanges of Shc vs N-Shc gene expression. Neural-speci®c signaling properties should depend, at least in part, on neural-speci®c molecules functioning in combination with other common factors. The present results support the view that N-Shc can modulate neuronal signaling by using multiple signaloutputs and switching with Shc. Thus, we assume that N-Shc-containing signaling complexes would exert speci®c and dynamic modulatory functions in mature neurons such as the reorganization of neuronal cytoskeleton and/or modulation of neurotransmission.
Materials and methods
Cell cultures and reagents
PC12 cells were grown in RPMI medium containing 10% horse serum and 5% fetal bovine serum (FBS). COS-1 cells and v-src-transformed 3Y1 ®broblasts (SR-3Y1) were maintained in DMEM/F12 medium supplemented with 10% FBS. SH-SY5Y cells were grown in 10% FBS-containing RPMI medium. NGF and EGF were purchased from Toyobo.
Antibodies
Phosphospeci®c antibodies to N-Shc pY259 and pY286 were raised against residues 254 ± 265 (with phosphorylated Y259) and residues 281 ± 292 (with phosphorylated Y286). Both antibodies were anity-puri®ed according to standard procedures followed by removing reactivity against unphosphorylated N-Shc (by absorption to a column containing the relevant unphosphorylated peptide). Anti-T7 peptide antibody was obtained from Novagen; and anti-pTyr antibody 4G10, from Upstate Biotechnology. Anti-Trk, anti-myc (9E10), anti-Grb2, anti-EGF receptor, anti-C3G and anti-GST were purchased from Santa Cruz Biotechnology; and anti-ACTIVE MAPK and anti-Erk1/2, from Promega. Antiv-src came from Calbiochem, and anti-Crk and anti-pTyr antibody RC20 were procured from Transduction Laboratories.
Plasmids and transient transfection experiments
Point mutations in N-Shc cDNA were generated by using a QuickChange site-directed mutagenesis kit (Stratagene); the desired changes were veri®ed by sequencing. The WT and mutated p52 N-Shc cDNAs were cloned into the pGEX ± 4T-1 vector (Amersham-Pharmacia) or pCMV1 mammalian expression vector (Anderson et al., 1989) . The WT and 3F mutant of human p52 Shc cDNAs (Gotoh et al., 1996) with the T7 peptide (ASMTGGQQMGR) tag at the amino terminus were subcloned into pCMV1. The myc-tagged Erk2 cDNA (Howe et al., 1992) was subcloned into the pCI vector (Promega) to generate pCI-MycErk2. pCAGGS-CrkI encodes human CrkI (Ichiba et al., 1997) . Cells in 100-mm dishes were transfected with 6 mg (PC12 cells) or 4 mg (COS-1 or SR-3Y1 cells) of plasmids by use of LipofectAmine Plus (Invitrogen). The eciency of transfection into PC12 cells was in the range of 10 ± 15% in these experiments. To express equal amounts of Shc and N-Shc proteins, we transfected cells with Shc and N-Shc expression plasmids at the ratio of 2:1.
Gal4 ± luciferase assay
Elk-1 activation was measured by using a transient transcriptional activation assay (PathDetect System, Stratagene). Along with additional test plasmids, 0.15 mg of plasmid encoding a Gal4 ± Elk1 fusion protein, 0.15 mg of Gal4-luciferase reporter construct and 0.15 ng of SV40 promoter-Renilla luciferase construct were used to transfect PC12 cells in 24-well plates. On the second day following transfection, cells were stimulated with NGF for 4.5 h or left untreated. Cell lysates were assayed on a TD-20/20 Luminometer using a Dual-Luciferase system (Promega).
Immunoprecipitation and peptide-affinity purification
Lysates from control or stimulated cells were immunoprecipitated as described previously (Nakamura et al., 1996) . For peptide-anity puri®cation, phosphopeptides were synthesized by standard procedures (Bex Corp.) , and the authenticity of the phosphopeptides was con®rmed by mass spectrometry. Cell lysates were incubated with biotinylated peptides immobilized on Streptavidin-Agarose (Upstate Biotechnology) or peptides immobilized on NHS-Sepharose (Amersham-Pharmacia). The anity beads were washed four times with the lysis buer. Immunoprecipitates or proteins bound on the anity beads were resolved by SDS ± PAGE. Silver staining was performed with a kit from DAIICHI Chemicals. Transfer to PVDF membranes (Millipore) and immunoblotting were performed as described . The amount of phosphorylated Erk2 was determined by densitometric analysis using an NIH image and normalized by total amount of transfected Erk2.
Tryptic phosphopeptide mapping
For in vitro phosphorylation, GST-fused WT or mutant NShc protein (2 mg) was incubated with TrkA immunoprecipitated from NGF-treated PC12 cell lysates , intracellular domain of TrkB prepared from baculovirus-infected Sf9 cells (Iwasaki et al., 1997) , immunopuri®ed v-Src kinase (van der Geer et al., 1996b) or immunoprecipitated and EGF-treated EGF receptor (Gotoh et al., 1997) in a phosphorylation buer containing 10 mCi of [g-32 P]ATP (5000 Ci/mmol; Amersham-Pharmacia) at 308C for 30 min. In vivo labeling of cellular phosphoproteins and stimulation with EGF were carried out as previously described (Gotoh et al., 1997) . The lysates from the in vivolabeled and EGF-treated cells expressing T7-tagged N-Shc were immunoprecipitated with anti-T7 antibody. The in vitroor in vivo-phosphorylated N-Shc proteins were resolved by SDS ± PAGE, and transferred onto PVDF membranes. Proteins on the membranes were digested with trypsin and eluted from the membrane by standard methods (Boyle et al., 1991) . Tryptic digests were resolved by electrophoresis at 1000 V for 30 min at pH 8.9 by the thin-layer electrophoresis system (Nippon Eido) and chromatography in phosphochromobuer.
GST pull-down assay
Stratagene TKX1 competent cells carrying the Elk tyrosine kinase gene were used to obtain the WT and various Y/F mutants of GST-fused N-Shc protein that were tyrosinephosphorylated in E. coli. Elk has been shown to have a broad speci®city and phosphorylate a number of proteins in bacteria (Simcox et al., 1994) . Unphosphorylated GST ± NShc was prepared from JM109. GST ± N-Shc proteins puri®ed by use of glutathione-Sepharose (Amersham-Pharmacia) were incubated with COS-1 lysates. The washed beads were boiled in SDS-sample buer, and the bound proteins were analysed by immunoblotting.
